Immunogenetic prediction of pulmonary fibrosis in systemic sclerosis

Lancet. 1991 Sep 14;338(8768):661-2. doi: 10.1016/0140-6736(91)91235-m.

Abstract

75 systemic sclerosis patients were independently tested for pulmonary fibrosis, autoantibodies, and MHC class II genes. 24 of 42 (57%) patients with pulmonary fibrosis had either HLA DR3/DRw52a or anti-Scl-70 vs 2 of 33 (6%) patients without pulmonary fibrosis. The presence of DR3/DRw52a or anti-Scl-70 gives a relative risk of 16.7 for the development of pulmonary fibrosis in a patient with scleroderma--a risk substantial enough to require careful monitoring of these patients and treatment at an early stage of disease.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Autoantibodies / analysis
  • DNA / analysis
  • HLA-DR3 Antigen / genetics
  • HLA-DR5 Antigen / genetics
  • Haplotypes / genetics
  • Humans
  • Nuclear Proteins / immunology
  • Probability
  • Pulmonary Fibrosis / etiology*
  • Pulmonary Fibrosis / immunology
  • Scleroderma, Systemic / complications*
  • Scleroderma, Systemic / immunology

Substances

  • Autoantibodies
  • HLA-DR3 Antigen
  • HLA-DR5 Antigen
  • Nuclear Proteins
  • Scl 70 antigen, human
  • DNA